Cimeio Therapeutics Presents Additional Proof-of-Concept Data for SCIP Platform

CAMBRIDGE, Mass. & BASEL, Switzerland–(BUSINESS WIRE)–Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, presented data for its CD45 Shielded Cell & Immunotherapy Pair (SCIP) program at the American Society of Gene and Cell Therapy’s Annual Meeting in Los Angeles. The findings build upon prior successful studies…